Craig-Hallum Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Buy
More News related to ONXX
- Onyx Pharmaceuticals Announces December 2009 Investor Events
- Notable Mergers and Acquisitions of the Day 11/16: CSCO, MOT, TTMI, ONXX
- Onyx Pharmaceuticals (ONXX) Completes Acquisition of Proteolix
- Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc.
- Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com
More News related to New Coverage
- Green Mountain (GMCR) Will Likely Win Diedrich Coffee (DDRX) Bidding War - Analyst
- SkyPeople (SPU) Acquires Yingkou Trusty Fruits in $3.3M Transaction
- GE (GE) Said to Restart NBC Universal Acquisition Talks -WSJ
- Diedrich Coffee (DDRX) Comments on Green Mountain Coffee Roasters' (GMCR) Revised Offer
- Peet's (PEET) Issues Statement Following News Diedrich (DDRX) Says Green Mountain (GMCR) Revised Offer is 'Superior'
Craig-Hallum initiates coverage on Onyx Pharmaceuticals (Nasdaq: ONXX) with a Buy. Price target $35.
To see more analyst ratings on ONXX Click Here.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
+0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
